An active long-term life science investor, focusing on biotech and pharmaceutical investments globally.
flerie.com (opens in a new tab)Investor relations
The next pillar of metabolic medicine.
A first-in-class, oral, once-daily muscle therapy. Phase I complete, mechanism published in Cell, and Phase II-ready.
Key highlights
Subjects dosed
Phase I complete
Published 2025
Motso et al.
Patents granted
Thousands of compounds
Oral dosing
Once daily
In class
GRK2-biased β₂ modulation
Our investors
Backed by long-term life-science investors.
Atrogi is backed by Flerie, Korea Investment Partners (KIP) and a network of private investors.
Raised from investors since inception
Incl. a SEK 90M rights issue
One of Asia's leading venture capital and private equity firms, headquartered in Seoul. Anchor investor in our SEK 90 million rights issue in 2020.
koreainvestment.com (opens in a new tab)Non-dilutive funding
Recognised by research funders.
Grants from European and Swedish innovation programmes, awarded in recognition of our receptor-signaling discoveries.
In non-dilutive grants
European and Swedish funders
Eurostars, run by the Eureka network with the European Commission, funds research-driven SMEs. Atrogi has received Eurostars funding twice, including for an obesity project in 2020.
eurekanetwork.org (opens in a new tab)
Sweden's innovation agency, which funds research and innovation projects.
vinnova.se (opens in a new tab)
Sweden's national strategic innovation programme for life science. Awarded in recognition of our receptor-signaling discovery.
swelife.se (opens in a new tab)Milestones
Development timeline.
From academic discovery to a Phase II-ready clinical asset.
- 2008Academic Discovery (completed)
- 2013Atrogi Founded (completed)
- 2020SEK 90M Raised (completed)
- 2022–23Phase I Complete (69 subjects) (completed)
- 2025Cell Publication (completed)
- 2025CEO Appointed (Paul Little) (completed)
- 2026ATTRACTIVE 3 (PoC) (upcoming)Next
- 2026+ATTRACTIVE 4 (GLP-1 combo) (upcoming)
Investors and partners
Phase II-ready.
Let's talk.
Investors
Request the investor deck
Phase I data, market analysis and Phase II plans.
Partners
Explore a partnership
Pharma business development, licensing and clinical collaboration.